MetaCap

Beam Therapeutics (BEAM) vs Replimune Group (REPL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Replimune Group (REPL) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 107.3% versus a loss of 5.9%. Over five years, REPL leads with a -34.2% price change compared with -73.4% for BEAM. Beam Therapeutics is the larger company by market cap ($2.16 billion vs $1.81 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BEAM-5.90%REPL+107.28%
+165%+36%-93%
Nov 21, 20251 yearNov 20, 2026
BEAM-76.70%REPL-44.32%
+5%-47%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BEAM versus REPL key metrics
MetricBEAMREPL
Share price$20.90$19.07
Market cap$2.16B$1.81B
1-day change-0.19%-0.83%
YTD return-24.60%+96.19%
1-year return-5.90%+107.28%
5-year return-73.44%-34.24%
EPS (TTM)$-0.87$-2.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$139.74M—
Revenue growth (YoY)+120.01%—
Net income (latest FY)$-79.99M$-313.94M
Operating margin-274.57%—
Net margin-57.24%—
52-week high$38.26$23.54
52-week low$20.44$1.50
Distance from 52-week high-45.37%-18.99%
Analyst consensusstrong_buybuy
Avg. price target upside+138.52%+33.72%
Average volume2.04M2.48M
Shares outstanding103.50M94.80M
Employees557465
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • REPL has outperformed BEAM by 113.2 percentage points over the past year.

About Beam Therapeutics

BEAM stock →

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees

About Replimune Group

REPL stock →

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees

BEAM vs REPL FAQ

Which is bigger, Beam Therapeutics or Replimune Group?

Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.16B compared with $1.81B for Replimune Group (REPL).

Which stock has performed better over the past year, BEAM or REPL?

REPL returned +107.28% over the past 12 months, compared with -5.90% for BEAM (price return, excluding dividends). Past performance does not predict future results.

Are Beam Therapeutics and Replimune Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons